Oruka Therapeutics Inc. (ORKA)
NASDAQ: ORKAHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
ORKA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.26B
- EPS (TTM)
- -$1.94
- Dividend yield
- None
- Ex-dividend date
- Aug 29, 2024
- 52-week range
- 20.25 – 115.52
- Day range
- 78.52 – 81.40
- Volume / Avg
- 809.89K / 889.85K
- Beta
- —
- Shares outstanding
- 66.21M
52-week range
ORKA stock today
Oruka Therapeutics (ORKA) closed at $79.50 on Oct 7, down 0.85% (-$0.68), versus the S&P 500's 0.22% decline. Shares are 31.2% below their 52-week high of $115.52, set on Aug 19, 2026 and 292.6% above the 52-week low of $20.25, in the middle of the past year's range. ORKA is up 162.3% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 286.5%.
Oruka Therapeutics has posted a net loss over the last twelve months (EPS of -$1.94), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Oruka Therapeutics
Company profileOruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001.
- Sector
- Health Care
- Industry
- Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CEO
- Dr. Lawrence Otto Klein Ph.D.
- Headquarters
- Menlo Park, CA
- Employees
- 68
- Website
- orukatx.com
Financial highlights
Full financialsOruka Therapeutics reported a net loss of $105.4 million, compared with a loss of $5.3 million a year earlier.
| Fiscal year | FY 2025 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | — | $0 | $0 | $0 | $0 |
| Growth | — | — | — | — | — |
| Net income | $-105.43M | $-5.34M | $-9.93M | $-19.32M | $-9.74M |
| EPS (diluted) | — | $-0.37 | $-0.69 | $-1.39 | $-2.07 |
Analyst forecast
ForecastConsensus (13 analysts)
strong_buy
Avg. price target
$155.00+94.97%
- Strong buy 2
- Buy 11
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Q2 2025)
- Aug 11, 2025
- EPS actual vs est.
- $-0.46 vs —
Dividends
Dividend history- Annual dividend
- $0.00
- Last payment
- $19.36
- Ex-dividend date
- Aug 29, 2024
Oruka Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LNTHLantheus Holdings Inc. | 100.18 | +0.23% | $6.54B | vs ORKA |
| NEOGNeogen Corporation | 11.68 | -2.34% | $2.55B | vs ORKA |
| CLDXCelldex Therapeutics Inc. | 30.43 | -1.85% | $2.39B | vs ORKA |
| NTLAIntellia Therapeutics Inc. | 11.71 | -5.34% | $1.64B | vs ORKA |
| QDELQuidelOrtho Corporation | 12.31 | -2.07% | $844.16M | vs ORKA |
| ACHVAchieve Life Sciences Inc. | 7.24 | +2.99% | $746.46M | vs ORKA |
| TKNOAlpha Teknova Inc. | 8.71 | -0.46% | $467.62M | vs ORKA |
| MYGNMyriad Genetics Inc. | 4.28 | 0.00% | $409.38M | vs ORKA |
Indexes, lists and sector
Appears in lists
Oruka Therapeutics stock FAQ
What is Oruka Therapeutics's stock price today?
ORKA last traded at $79.50 as of Oct 7, 4:00 PM EDT, down 0.85% on the day. Prices are delayed at least 15 minutes.
Does Oruka Therapeutics pay a dividend?
Yes. Oruka Therapeutics pays $0.00 per share annually. The most recent dividend of $19.36 had an ex-dividend date of Aug 29, 2024.
Who is Oruka Therapeutics's CEO?
Dr. Lawrence Otto Klein Ph.D. is the chief executive officer of Oruka Therapeutics Inc., which has about 68 employees.
Has ORKA ever split its stock?
Yes. The most recent ORKA stock split was a 1-for-12 split on Sep 3, 2024, one of 6 splits on record.
What is the ORKA 52-week high?
The 52-week high for ORKA is $115.52 and the 52-week low is $20.25. The stock is currently 31.2% below its high.